Literature DB >> 6757269

Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase.

J D Tissot, P Schneider, J Hauert, M Ruegg, E K Kruithof, F Bachmann.   

Abstract

Two different plasmatic plasminogen activators (PA) can be demonstrated after sodium dodecyl sulfate polyacrylamide gel electrophoresis of plasma freshly collected from resting volunteers, followed by transfer of the gels onto plasminogen-rich fibrin-agarose plates. These two PA are also present in plasmas deficient in coagulation Factor XI, Factor XII, prekallikrein, or high molecular weight-kininogen. The slower-moving PA has an apparent 85,000 Mr and is immunologically unrelated to urokinase (UK). The faster moving PA was isolated by immunoadsorption of plasma on anti-UK IgG coupled to Sepharose 4B and appears to be identical to urinary high molecular weight-UK.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6757269      PMCID: PMC370351          DOI: 10.1172/jci110733

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  12 in total

1.  Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates.

Authors:  B R Binder; J Spragg; K F Austen
Journal:  J Biol Chem       Date:  1979-03-25       Impact factor: 5.157

2.  Activation of plasminogen by human plasma kallikrein.

Authors:  R W Colman
Journal:  Biochem Biophys Res Commun       Date:  1969-04-29       Impact factor: 3.575

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture.

Authors:  B Astedt; L Holmberg
Journal:  Nature       Date:  1976-06-17       Impact factor: 49.962

5.  The participation of plasma thromboplastin antecedent (Factor XI) in contact-activated fibrinolysis.

Authors:  H Saito
Journal:  Proc Soc Exp Biol Med       Date:  1980-06

6.  Isolation and characterization of urokinase from human plasma.

Authors:  T C Wun; W D Schleuning; E Reich
Journal:  J Biol Chem       Date:  1982-03-25       Impact factor: 5.157

7.  No crossreaction between circulating plasminogen activator and urokinase.

Authors:  B Astedt
Journal:  Thromb Res       Date:  1979       Impact factor: 3.944

8.  Effect of urokinase antiserum on plasminogen activators: demonstration of immunologic dissimilarity between plasma plasminogen activator and urokinase.

Authors:  C S Kucinski; A P Fletcher; S Sherry
Journal:  J Clin Invest       Date:  1968-06       Impact factor: 14.808

9.  Purification and characterization of human vascular plasminogen activator.

Authors:  B Aasted
Journal:  Biochim Biophys Acta       Date:  1980-02-27

10.  A study of proteases and protease-inhibitor complexes in biological fluids.

Authors:  A Granelli-Piperno; E Reich
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

View more
  10 in total

1.  Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.

Authors:  Manfred Schmitt; Karin Mengele; Apostolos Gkazepis; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2008-10-15       Impact factor: 2.860

2.  Identification of a plasminogen activator derived from nasopharyngeal carcinoma.

Authors:  T Kosugi; G W Huang; M Nakamura; S Koja; H T Nong
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

3.  Immunological comparison between human and rat plasminogen activators in blood and the vessel wall.

Authors:  A Kjaeldgaard; B Larsson; B Astedt
Journal:  J Clin Pathol       Date:  1984-10       Impact factor: 3.411

4.  Tear plasminogen activators--indicators of epithelial cell destruction. The effect of scraping, n-heptanol debridement, and alkali burn of the cornea on the plasminogen activator activity of rabbit tears.

Authors:  A Berta; F J Holly; J Tözsér; T F Holly
Journal:  Int Ophthalmol       Date:  1991-11       Impact factor: 2.031

5.  Transport of urokinase across the intestinal tract of normal human subjects with stimulation of synthesis and/or release of urokinase-type proteins.

Authors:  N Toki; H Sumi; K Sasaki; I Boreisha; K C Robbins
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

6.  Human tissue-type plasminogen activator. Production in continuous serum-free cell culture and rapid purification.

Authors:  E K Kruithof; W D Schleuning; F Bachmann
Journal:  Biochem J       Date:  1985-03-15       Impact factor: 3.857

7.  The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related.

Authors:  L A Erickson; C M Hekman; D J Loskutoff
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

8.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.

Authors:  J D Vassalli; D Baccino; D Belin
Journal:  J Cell Biol       Date:  1985-01       Impact factor: 10.539

9.  The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes.

Authors:  A Estreicher; J Mühlhauser; J L Carpentier; L Orci; J D Vassalli
Journal:  J Cell Biol       Date:  1990-08       Impact factor: 10.539

10.  Inhibitory effect of oversulfated fucoidan on invasion through reconstituted basement membrane by murine Lewis lung carcinoma.

Authors:  S Soeda; S Ishida; H Shimeno; A Nagamatsu
Journal:  Jpn J Cancer Res       Date:  1994-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.